EHA 2023 | Exploring the role of CAR-T therapy in MCL & impact of prior treatment with BTKi or bendamustine
Nausheen Ahmed, MD, University of Kansas Medical Center, Kansas City, MO, explores the evolving role of CAR-T therapy in mantle cell lymphoma (MCL). Brexucabtagene autoleucel (brexu-cel) is currently approved in the US for second-line therapy of MCL, whilst in Europe, it is approved in the third-line setting. Dr. Ahmed comments on the interest in CAR-T therapy for high-risk patients with MCL and highlights the comparable outcomes between patients who have or have not received BTK inhibitors (BTKi) or bendamustine prior to CAR-T treatment. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kite: consulting, BMS: advisory board
